Is Enliven Therapeutics Stock a Good Investment?
Enliven Therapeutics Investment Advice | ELVN |
- Examine Enliven Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Enliven Therapeutics' leadership team and their track record. Good management can help Enliven Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Enliven Therapeutics' business and its evolving consumer preferences.
- Compare Enliven Therapeutics' performance and market position to its competitors. Analyze how Enliven Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Enliven Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Enliven Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Enliven Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Enliven Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Enliven Therapeutics Stock
Researching Enliven Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Enliven Therapeutics was currently reported as 5975.16. The company recorded a loss per share of 1.89. Enliven Therapeutics had not issued any dividends in recent years. The entity had 1:4 split on the 24th of February 2023.
To determine if Enliven Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enliven Therapeutics' research are outlined below:
| Enliven Therapeutics generated a negative expected return over the last 90 days | |
| Enliven Therapeutics has high historical volatility and very poor performance | |
| Enliven Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enliven Therapeutics generates negative cash flow from operations | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Enliven Therapeutics Shares Up 11.3 percent - Heres Why - MarketBeat |
Enliven Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enliven Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enliven Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Enliven Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Enliven Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-10 | 2023-06-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2024-03-14 | 2023-12-31 | -0.54 | -0.47 | 0.07 | 12 | ||
2024-08-13 | 2024-06-30 | -0.55 | -0.41 | 0.14 | 25 | ||
2023-05-11 | 2023-03-31 | -0.63 | -0.8 | -0.17 | 26 | ||
2022-10-25 | 2022-09-30 | -1 | -0.72 | 0.28 | 28 | ||
2022-08-03 | 2022-06-30 | -2.05 | -1.76 | 0.29 | 14 | ||
2020-11-05 | 2020-09-30 | -3.21 | -2.88 | 0.33 | 10 | ||
2022-03-15 | 2021-12-31 | -3 | -2.12 | 0.88 | 29 |
Enliven Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.05 B.Market Cap |
|
Enliven Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.33) | (0.32) |
Determining Enliven Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Enliven Therapeutics is a good buy. For example, gross profit margin measures Enliven Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enliven Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Enliven Stock
As of the 22nd of January, Enliven Therapeutics shows the Standard Deviation of 3.49, variance of 12.18, and Mean Deviation of 2.45. Enliven Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enliven Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enliven Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enliven Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enliven Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enliven Therapeutics' Outstanding Corporate Bonds
Enliven Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enliven Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enliven bonds can be classified according to their maturity, which is the date when Enliven Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US29336TAC45 Corp BondUS29336TAC45 | View | |
| ENLC 65 01 SEP 30 Corp BondUS29336TAD28 | View | |
| ENLINK MIDSTREAM LLC Corp BondUS29336TAA88 | View | |
| EnLink Midstream Partners Corp BondUS29336UAD90 | View | |
| EnLink Midstream Partners Corp BondUS29336UAC18 | View | |
| EnLink Midstream Partners Corp BondUS29336UAF49 | View | |
| EnLink Midstream Partners Corp BondUS29336UAE73 | View | |
| EnLink Midstream Partners Corp BondUS29336UAG22 | View |
Understand Enliven Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Enliven Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 0.6785 | |||
| Mean Deviation | 2.45 | |||
| Coefficient Of Variation | (1,063) | |||
| Standard Deviation | 3.49 | |||
| Variance | 12.18 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | 0.6685 | |||
| Maximum Drawdown | 19.31 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 5.5 | |||
| Skewness | 0.4168 | |||
| Kurtosis | 2.0 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 0.6785 | |||
| Mean Deviation | 2.45 | |||
| Coefficient Of Variation | (1,063) | |||
| Standard Deviation | 3.49 | |||
| Variance | 12.18 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | 0.6685 | |||
| Maximum Drawdown | 19.31 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 5.5 | |||
| Skewness | 0.4168 | |||
| Kurtosis | 2.0 |
Consider Enliven Therapeutics' intraday indicators
Enliven Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enliven Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Enliven Therapeutics Corporate Filings
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Enliven Stock media impact
Far too much social signal, news, headlines, and media speculation about Enliven Therapeutics that are available to investors today. That information is available publicly through Enliven media outlets and privately through word of mouth or via Enliven internal channels. However, regardless of the origin, that massive amount of Enliven data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Enliven Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Enliven Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Enliven Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Enliven Therapeutics alpha.
Enliven Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Enliven Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Enliven Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts
Enliven Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Enliven Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Enliven Therapeutics' options.
Enliven Therapeutics Corporate Executives
Elected by the shareholders, the Enliven Therapeutics' board of directors comprises two types of representatives: Enliven Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enliven. The board's role is to monitor Enliven Therapeutics' management team and ensure that shareholders' interests are well served. Enliven Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enliven Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Lyssikatos | CoFounder Officer | Profile | |
| Benjamin Hohl | CFO Development | Profile | |
| Anish PharmD | CoFounder COO | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Enliven Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.